215 related articles for article (PubMed ID: 29290804)
1. An Albumin-binding Polypeptide Both Targets Cytotoxic T Lymphocyte Vaccines to Lymph Nodes and Boosts Vaccine Presentation by Dendritic Cells.
Wang P; Zhao P; Dong S; Xu T; He X; Chen M
Theranostics; 2018; 8(1):223-236. PubMed ID: 29290804
[No Abstract] [Full Text] [Related]
2. Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo.
Wang P; Dong S; Zhao P; He X; Chen M
Biomaterials; 2018 Nov; 182():92-103. PubMed ID: 30107273
[TBL] [Abstract][Full Text] [Related]
3. Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.
Dong S; Xu T; Wang P; Zhao P; Chen M
Acta Pharmacol Sin; 2017 Jun; 38(6):914-923. PubMed ID: 28414197
[TBL] [Abstract][Full Text] [Related]
4. A Comparison Study of iTEP Nanoparticle-Based CTL Vaccine Carriers Revealed a Surprise Relationship between the Stability and Efficiency of the Carriers.
Dong S; Xu T; Zhao P; Parent KN; Chen M
Theranostics; 2016; 6(5):666-78. PubMed ID: 27022414
[TBL] [Abstract][Full Text] [Related]
5. Direct Loading of iTEP-Delivered CTL Epitope onto MHC Class I Complexes on the Dendritic Cell Surface.
Dong S; Wang P; Zhao P; Chen M
Mol Pharm; 2017 Oct; 14(10):3312-3321. PubMed ID: 28789525
[TBL] [Abstract][Full Text] [Related]
6. Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers.
Cho S; Dong S; Parent KN; Chen M
J Drug Target; 2016; 24(4):328-39. PubMed ID: 26307138
[TBL] [Abstract][Full Text] [Related]
7. Delivered antigen peptides to resident CD8α
Wang L; Wang Z; Qin Y; Liang W
Eur J Pharm Biopharm; 2020 Feb; 147():76-86. PubMed ID: 31887349
[TBL] [Abstract][Full Text] [Related]
8. Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses.
Keller S; Wilson JT; Patilea GI; Kern HB; Convertine AJ; Stayton PS
J Control Release; 2014 Oct; 191():24-33. PubMed ID: 24698946
[TBL] [Abstract][Full Text] [Related]
9. Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses.
Kang S; Ahn S; Lee J; Kim JY; Choi M; Gujrati V; Kim H; Kim J; Shin EC; Jon S
J Control Release; 2017 Jun; 256():56-67. PubMed ID: 28428066
[TBL] [Abstract][Full Text] [Related]
10. Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity.
Dong S; Subramanian S; Parent KN; Chen M
J Control Release; 2020 Dec; 328():653-664. PubMed ID: 32961248
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability.
Moynihan KD; Holden RL; Mehta NK; Wang C; Karver MR; Dinter J; Liang S; Abraham W; Melo MB; Zhang AQ; Li N; Gall SL; Pentelute BL; Irvine DJ
Cancer Immunol Res; 2018 Sep; 6(9):1025-1038. PubMed ID: 29915023
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Polymeric Mixed Micelles Targeting Lymph Nodes Trigger Enhanced Cellular and Humoral Immune Responses.
Li C; Zhang X; Chen Q; Zhang J; Li W; Hu H; Zhao X; Qiao M; Chen D
ACS Appl Mater Interfaces; 2018 Jan; 10(3):2874-2889. PubMed ID: 29285934
[TBL] [Abstract][Full Text] [Related]
13. Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy.
Qian Y; Jin H; Qiao S; Dai Y; Huang C; Lu L; Luo Q; Zhang Z
Biomaterials; 2016 Aug; 98():171-83. PubMed ID: 27192420
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
15. Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL.
Luketic L; Delanghe J; Sobol PT; Yang P; Frotten E; Mossman KL; Gauldie J; Bramson J; Wan Y
J Immunol; 2007 Oct; 179(8):5024-32. PubMed ID: 17911587
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW
Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479
[TBL] [Abstract][Full Text] [Related]
18. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
Dell K; Klein C; Gissmann L
Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
[TBL] [Abstract][Full Text] [Related]
19. A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination.
Gálvez-Cancino F; Roco J; Rojas-Colonelli N; Flores C; Murgas P; Cruz-Gómez S; Oyarce C; Varas-Godoy M; Sauma D; Lladser A
Vaccine; 2017 Jul; 35(33):4148-4154. PubMed ID: 28666759
[TBL] [Abstract][Full Text] [Related]
20. Structural effects and lymphocyte activation properties of self-assembled polysaccharide nanogels for effective antigen delivery.
Miura R; Tahara Y; Sawada SI; Sasaki Y; Akiyoshi K
Sci Rep; 2018 Nov; 8(1):16464. PubMed ID: 30405172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
